期刊文献+

狼疮肾炎患者的sHLA-Ⅰ类分子定量检测及mRNA表达水平的研究

STUDY ON QUANTIFICATION OF SOLUBLE HLA CLASS Ⅰ MOLECULES AND mRNA EXPRESSION LEVELS IN PATIENTS WITH LUPUS NEPHRITIS
下载PDF
导出
摘要 目的 :定量检测狼疮肾炎 (LN)患者的sHLA -Ⅰ类分子水平 ,并对其变化的可能机制从分子水平作初步探讨。方法 :ELISA双抗夹心法检测血浆的sHLA -Ⅰ类分子水平 ;RT -PCR检测PBMCHLA -Ⅰ类分子α链mRNA的表达水平。结果 :2 3例LN患者的血浆sHLA -Ⅰ类分子水平为 (96 1.40± 32 4.2 4) μg/L ,LN患者与正常人相比明显增高 (P <0 .0 1) ;LN患者PBMCHLA -Ⅰ类分子α3 结构域 -C末端及变位剪接片段mRNA表达水平明显高于正常人 (P <0 .0 1,P <0 .0 5 )。结论 :LN患者血浆的sHLA -Ⅰ类分子水平明显增高 ,增高的可能机制之一是PBMCHLA -Ⅰ类分子α链变位剪接 ,使得 39KD的sHLA Objective:To quantify soluble HLA Class Ⅰ (sHLA-Ⅰ)molecules,to study the expression levels of PBMC HLA-Ⅰ molecule α chain mRNA in patients with Lupus nephritis(LN),and to investigate the molecular mechanism of changes in plasma levels of sHLA-Ⅰ molecules in patients with LN.Methods:The plasma levels of sHLA-Ⅰ molecules were measured by sandwich enzyme-linked immunosorbent assay.PBMC HLA-Ⅰ molecule α chain mRNA levels were tested by RT-PCR.Results:The plasma sHLA-Ⅰ molecule concentration was 961.40±324.24μg/L in 23 patients with LN,and 522.45±162.04μg/L in 24 normal controls,revealing significantly difference between them(P<0.01);The LN patients PBMC HLA-Ⅰ molecule α 3 domain-carboxyl terminal and the alternatively spliced mRNA levels increased than those of normal controls(P<0.01,P<0.05).Conclusions:The plasma sHLA-Ⅰ molecule concentration in patients with LN is higher than normal controls,and one of the possible mechanism of the increased plasma levels of sHLA-Ⅰ molecule concentration in LN patients is the PBMC HLA-Ⅰ molecule α chain alternatively spliced mRNA increased,resulting in the elevation of the 39 KD sHLA-Ⅰ molecule.
出处 《中国现代医学杂志》 CAS CSCD 2001年第8期36-37,共2页 China Journal of Modern Medicine
关键词 狼疮性肾炎 可溶性人类白细胞抗原 逆转录聚合酶链反应信使 Lupus Nephritis Soluble Human Leukocyte Antigens(sHLA) Reverse Transcriptase Polymerase Chain Reaction Untranslated Regions
  • 引文网络
  • 相关文献

参考文献1

二级参考文献9

  • 1查国章,王贵喜.正常人血中可溶性HLA-IgG复合物的初步研究[J].湖南医科大学学报,1995,20(2):103-106. 被引量:1
  • 2Van Rood JJ,Van Leeuvven A,Van Santen MCT.Anti-HLA-9 inhibitor in normal human serum.Natrure,1970;226:366~367
  • 3Burlingham WJ,Souble MHC.immunoregulation,and tolerance:A progress report.Hum Immunol,2000;61:1316~1319
  • 4Tsuchiya N,Shiota M,Yamaguchi A,et al.Elevated serum level of soluble HLA class I antigens in Patients with systemic lupus erythematosus.Arthritis Rheum,1996;39:792~796
  • 5Wolf RE,Adamashvili IM,Gelder FB,et al.Soluble HLA-I in rheumatic diseasesm.Hum Immunol,1998;59:644~649
  • 6Buelow R,Burlingham WJ,Clayberger C.Immunomodulation by soluble HLA Class I. Transplantation,1995;59:649
  • 7Van Buskirk AM,Wakely E,Sirak JH.Patterns of allosensitization in allograft recipients;long-term cardiac allograft acceptance is associated with active alloantibody production in conjunction with active inhibition of alloreactive DTH.Transplantation,1998;65:1115
  • 8郑敏,朱铁城.SLE患者B淋巴细胞增殖功能测定及其临床意义[J].中华皮肤科杂志,1990,23(2):90-92. 被引量:35
  • 9汤爱国,罗学宏,李宝花.SLE患者ENA多肽抗体和IFANA的检测及其临床意义[J].中国现代医学杂志,2000,10(8):63-64. 被引量:7

共引文献2

;
使用帮助 返回顶部